Devices › Stent, superficial femoral artery, drug-eluting
Device brand name · Stent superficial femoral artery drug-eluting
ELUVIA Drug-Eluting Vascular Stent System: medical device reports filed with FDA
1,079 reports name it, 2016–2026. Manufacturer given most often on reports: Boston Scientific. Product code NIU.
- 1,079
- device reports naming the brand
- 0% of all MAUDE reports · about 104 a year
- 50
- reports, 12 months to August 2026
- 61 in the 12 months before
- 36.6%
- classified as malfunction
- 29.4% across the product code
- 0.6%
- classified as death, as reported
- 6 reports · not verified by FDA
1,079 medical device reports received by FDA name the brand "ELUVIA Drug-Eluting Vascular Stent System" (stent superficial femoral artery drug-eluting); the manufacturer given most often on reports is Boston Scientific; received from March 2016 to August 2026. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.
50 reports arrived in the 12 months to August 2026, down 18% from 61 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (62.8%), malfunction (36.6%) and death (0.6%); across all stent, superficial femoral artery, drug-eluting reports (product code NIU) death is recorded in 0.6% and malfunction in 29.4%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are activation, positioning or separation problem (27.1%), material deformation (18.7%) and fracture (10.4%). The patient problems coded most often are restenosis, thrombosis/thrombus and obstruction/occlusion. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 2,857 reports carrying product code NIU. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Activation, positioning or separation problem | 292 | 27.1% | 16.2% |
| Material deformation | 202 | 18.7% | 8.4% |
| Fracturea broken bone | 112 | 10.4% | 11% |
| Entrapment of device | 89 | 8.2% | 3.5% |
| Premature activation | 57 | 5.3% | 2.5% |
| Activation failure | 47 | 4.4% | 3% |
| Difficult to removethe device was hard to remove | 41 | 3.8% | 2.4% |
| Stretched | 34 | 3.2% | 1.4% |
| Difficult or delayed positioning | 33 | 3.1% | 1.2% |
| Positioning problem | 27 | 2.5% | 1.2% |
| Difficult to advance | 19 | 1.8% | 0.8% |
| Failure to advance | 19 | 1.8% | 1.1% |
| Material integrity problema problem with the device material | 16 | 1.5% | 0.6% |
| Deformation due to compressive stress | 15 | 1.4% | 1.5% |
| Bent | 13 | 1.2% | 0.7% |
| Defective devicethe device was defective | 12 | 1.1% | 0.5% |
| Difficult or delayed activation | 12 | 1.1% | 0.5% |
| Positioning failure | 12 | 1.1% | 0.6% |
| Detachment of device or device componentpart of the device came off | 11 | 1% | 0.4% |
| Breakthe device broke | 8 | 0.7% | 1.3% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Restenosis | 151 | 14% |
| Thrombosis/thrombus | 105 | 9.7% |
| Obstruction/occlusion | 98 | 9.1% |
| Reocclusion | 74 | 6.9% |
| Painpain, site not specified | 72 | 6.7% |
| Thrombosis | 72 | 6.7% |
| Arteriosclerosis/ atherosclerosis | 50 | 4.6% |
| Occlusion | 39 | 3.6% |
| Ischemia | 28 | 2.6% |
| Vascular dissection | 26 | 2.4% |
| Claudication | 24 | 2.2% |
| Foreign body in patientpart of a device left in the patient | 20 | 1.9% |
| Device embedded in tissue or plaque | 19 | 1.8% |
| Numbnessnumbness | 15 | 1.4% |
| Ulcer | 14 | 1.3% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | ELUVIA Drug-Eluting Vascular Stent System | Product code NIU | All MAUDE reports |
|---|---|---|---|
| Reports | 1,079 | 2,857 | 26,136,888 |
| Share of that pool | — | 37.8% | 0% |
| Classified as death, per 1,000 reports | 6 | 6 | 9 |
| Classified as injury | 62.8% | 70% | 36.2% |
| Classified as malfunction | 36.6% | 29.4% | 62.3% |
| Filed by the manufacturer | 100% | 96.9% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code NIU
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Zilver Ptx Drug-Eluting Peripheral Stent | 727 | 9 | 0% |
| Zilver Ptx 35 Drug-Eluting Stent | 590 | 16 | 0.7% |
| ELUVIATM Drug-Eluting Vascular Stent System | 228 | 32 | 1.8% |
| Cypher Sirolimus-Eluting Coronary Stent | 15,051 | 0 | 10.3% |
| Evolution Biliary Controlled-Release Stent - Uncovered | 194 | 20 | 0% |
| Promus PREMIER | 6,159 | 111 | 6.3% |
| Zenith Fenestrated Graft | 163 | 0 | 20.2% |
| Zilver 635 Biliary Self Expanding Metal Stent | 362 | 13 | 0% |
| Zilver Flex 35 Vascular Self-Expanding Stent | 203 | 23 | 0.5% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about ELUVIA Drug-Eluting Vascular Stent System reports
How many FDA reports name ELUVIA Drug-Eluting Vascular Stent System?
1,079 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 50 in the latest 12 months.
What kinds of events are reported?
injury (62.8%), malfunction (36.6%) and death (0.6%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
activation, positioning or separation problem (27.1%), material deformation (18.7%), fracture (10.4%), entrapment of device (8.2%) and premature activation (5.3%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that ELUVIA Drug-Eluting Vascular Stent System was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.